Galectin Therapeutics is a development-stage company engaged in developing carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer. GALT also has a colorectal cancer program moving toward commercialization. The company’s lead product candidate is a candidate for cancer therapy: GM-CT-01. GR-MD-02 is the company’s lead product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis. For more information visit the company’s Web site at: www.galectintherapeutics.com
Aegis Capital Corp. is a full service retail and institutional broker-dealer located in New York City. Aegis Capital’s management is committed to providing the highest level of service to its clients. The firm realizes this goal by running an independent, conflict-free platform that is focused on enhancing the goals of clients by bringing unencumbered advice, which enables them to freely create a plan centered on each client. For more information on Aegis Capital, visit www.aegiscapcorp.com.
Let us hear your thoughts below: